Centessa Pharmaceuticals PLC- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Centessa Pharmaceuticals PLC 公司

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

Centessa Pharmaceuticals PLC簡介



公司代碼CNTA

公司名稱Centessa Pharmaceuticals PLC

上市日期May 28, 2021

CEOSaha (Saurabh)

員工數量77

證券類型Depository Receipt

年結日May 28

公司地址3rd Floor

城市ALTRINCHAM

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United Kingdom

郵編WA14 2DT

電話447391789784

網址https://www.centessa.com/

公司代碼CNTA

上市日期May 28, 2021

CEOSaha (Saurabh)

Centessa Pharmaceuticals PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Gregory M. (Greg) Weinhoff, M.D.

Chief Business Officer

77.08K

+16842.00%

Dr. Saurabh Saha, M.D., Ph.D.

Chief Executive Officer, Director

45.17K

--

Mr. Iqbal Hussain

General Counsel and Chief Compliance Officer, Company Secretary

--

Ms. Tia Bush

Chief Technology and Quality Officer

--

Dr. Francesco de Rubertis, Ph.D.

Non-Executive Independent Chairman of the Board

--

Dr. Arjun Goyal, M.D.

Non-Executive Independent Director

--

Dr. Brett I. W. Zbar, M.D.

Non-Executive Independent Director

--

Dr. Mary Lynne Hedley, Ph.D.

Non-Executive Independent Director

--

Dr. Samarth Kulkarni, Ph.D.

Non-Executive Independent Director

--

Ms. Carol Stuckley

Non-Executive Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Gregory M. (Greg) Weinhoff, M.D.

Chief Business Officer

77.08K

+16842.00%

Dr. Saurabh Saha, M.D., Ph.D.

Chief Executive Officer, Director

45.17K

--

Mr. Iqbal Hussain

General Counsel and Chief Compliance Officer, Company Secretary

--

Ms. Tia Bush

Chief Technology and Quality Officer

--

Dr. Francesco de Rubertis, Ph.D.

Non-Executive Independent Chairman of the Board

--

Dr. Arjun Goyal, M.D.

Non-Executive Independent Director

--

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 1月18日週日

持股股東

股東類型

持股股東

佔比

Medicxi Ventures (UK) LLP

13.67%

Avoro Capital Advisors LLC

7.40%

Adage Capital Management, L.P.

6.87%

Index Ventures SA

6.82%

General Atlantic LLC

5.04%

其他

60.19%

持股股東

佔比

Medicxi Ventures (UK) LLP

13.67%

Avoro Capital Advisors LLC

7.40%

Adage Capital Management, L.P.

6.87%

Index Ventures SA

6.82%

General Atlantic LLC

5.04%

其他

60.19%

股東類型

持股股東

佔比

Venture Capital

21.32%

Investment Advisor/Hedge Fund

20.31%

Hedge Fund

19.37%

Investment Advisor

16.87%

Private Equity

8.07%

Research Firm

1.42%

Individual Investor

0.61%

Bank and Trust

0.03%

Pension Fund

0.01%

其他

12.00%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

255

127.66M

87.41%

-17.58M

2025Q3

241

133.90M

109.10%

+4.79M

2025Q2

226

132.04M

110.14%

-1.07M

2025Q1

214

132.76M

108.57%

-12.24M

2024Q4

180

128.06M

101.80%

+5.92M

2024Q3

158

122.07M

88.34%

+22.15M

2024Q2

135

99.90M

89.43%

+12.17M

2024Q1

129

87.74M

96.45%

-9.01M

2023Q4

114

84.27M

95.12%

+1.65M

2023Q3

113

82.62M

96.02%

+2.24M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Medicxi Ventures (UK) LLP

19.96M

13.67%

--

Sep 30, 2025

Avoro Capital Advisors LLC

10.81M

7.4%

+5.81M

+116.16%

Sep 30, 2025

Adage Capital Management, L.P.

10.04M

6.87%

+1.63M

+19.42%

Sep 30, 2025

Index Ventures SA

9.96M

6.82%

--

Sep 30, 2025

General Atlantic LLC

7.37M

5.04%

-2.31M

-23.91%

Nov 26, 2025

Fidelity Management & Research Company LLC

6.24M

4.27%

+2.41M

+63.08%

Sep 30, 2025

Janus Henderson Investors

5.41M

3.7%

-1.12M

-17.21%

Sep 30, 2025

T. Rowe Price Associates, Inc.

4.80M

3.29%

-1.10M

-18.69%

Sep 30, 2025

Farallon Capital Management, L.L.C.

4.33M

2.97%

-198.00K

-4.37%

Sep 30, 2025

First Light Asset Management, LLC

3.64M

2.49%

-657.60K

-15.32%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Neuroscience and Healthcare ETF

3.56%

Virtus LifeSci Biotech Clinical Trials ETF

1.4%

Invesco Nasdaq Biotechnology ETF

0.23%

ProShares Ultra Nasdaq Biotechnology

0.23%

T Rowe Price Small-Mid Cap ETF

0.15%

iShares Biotechnology ETF

0.13%

Fidelity Fundamental Small-Mid Cap ETF

0.11%

iShares Intl Small Cap Equity Factor ETF

0.01%

Fidelity Nasdaq Composite Index ETF

0.01%

SPDR S&P International Small Cap ETF

0%

iShares Neuroscience and Healthcare ETF

佔比3.56%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.4%

Invesco Nasdaq Biotechnology ETF

佔比0.23%

ProShares Ultra Nasdaq Biotechnology

佔比0.23%

T Rowe Price Small-Mid Cap ETF

佔比0.15%

iShares Biotechnology ETF

佔比0.13%

Fidelity Fundamental Small-Mid Cap ETF

佔比0.11%

iShares Intl Small Cap Equity Factor ETF

佔比0.01%

Fidelity Nasdaq Composite Index ETF

佔比0.01%

SPDR S&P International Small Cap ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據